Hillary Gretton, MBA, CPP

Backed by the industry’s most experienced #IRT designers and specialists, Calyx IRT is the solution you can trust for effective #RTSM strategies that keep trials on track, even when they don’t go according to plan. Learn how. https://lnkd.in/g5ZzyK9T #ClinicalTrials #Randomization #TrialSupplyManagement

14

If you still don't know what's in #FDA's 2024 Data Monitoring Committee draft guidance, now is the time to catch up. Learn the implications of key updates from Advarra experts, Barbara Schneider, Ph.D., MBA and James Riddle. #data #clinicalresearch #biostatistics

16

Totally agree with Josh Bernoff here about naming your book. Catchy (title) plus briefly explanatory (subtitle) is the way to go. https://lnkd.in/gbxU7e7r Grab attention and memory. Then address understanding. Make both intriguing.

2

2 Comments

The 340B Drug Pricing Program has grown significantly in recent years. States have responded by passing additional legislation, creating a complex policy landscape that’s challenging for both manufacturers and providers. My colleagues explore pharma’s and states’ policy responses, analyze how successful these responses have been and offer recommendations for how pharma can adapt in a dynamic environment.  #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eJwm-NrN

8

This content is intended for U.S. audiences only. The countdown to Chicago is on, as we gear up for #ASCO24 in less than two weeks! For the first time, @AstraZeneca will headline not one, but TWO back-to-back plenary sessions in LUNG as well as a late-breaking study in BREAST. Our team is focused on treating cancers at earlier stages and across subtypes while advancing medicines and combination therapies that attack the disease from all angles, evidenced by our strong, diverse research to be presented in Chicago. Behind every data point is a patient, who deserves a personalised therapy that will give them a longer and healthier life. For each one, we’re pushing the boundaries of science, and I can’t wait to highlight our research advances in the coming weeks. Stay tuned! 🔬 For a more detailed preview of our #ASCO24 data presentations, please see our press release https://lnkd.in/ehH7tqFc #CancerResearch #oncology #MedicalAdvancements

224

3 Comments

Really interesting the paper from Journal of Managed Care & Specialty Pharmacy shared by Biosimilars Forum ... might the adalimumab biosimilar case in the US, if repeated with other #biosimilars, put at risk patients access to affordable therapies in the future due to a change in the #strategy of developers and manufactures of biosimilars? Food for thought ... #projectmanagement #businessdevelopment

1

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit. ....from the Citeline archives, via Sarah Karlin-Smith ********** In a court filing reported yesterday by Bloomberg Law reporter Celine Castronuovo, Amgen argues it will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for Enbrel. Like nearly all content in healthcare today, Amgen's storyline starts and sticks with the Standard Model, the cut-and-paste messaging that now sits at the extreme end of monotonous repetition. To wit: "Innovative medicines have enhanced and extended the lives of countless Coloradans. Recognizing the enormous investment of time and money needed to discover and develop these novel treatments, Congress rewarded those who bring new medicines to market with a period of patent exclusivity and pricing discretion. As numerous scholars have observed, the economic incentives provided by the federal patent system are crucial to Congress’s objective of promoting pharmaceutical research and development. One such medicine, Amgen’s pioneering drug ENBREL® provides life-changing relief to thousands of Coloradans who suffer from arthritis and other autoimmune diseases. Enbrel redefined the clinical course of moderate to severe rheumatoid arthritis...." etc., etc., etc., etc. All of which may be technically true, as "the scholars have observed", but if the objective for Amgen is an argument that persuades, the #StandardModel stopped working long ago. It also doesn't help when the 20 members of the Colorado drug pricing board and its advisory council come home from work and watch the local news, where the commercial breaks will be flooded with drug promotion, part of the media buy that comes from the industry spending $30 billion/year on DTC advertising. These things are connected. In a conversation with Bill Boulding, Dean of Duke University - The Fuqua School of Business around the same time as his interview with STAT, Frazier said one of the role's of business was in collaborating with government to reinvent the country. “The role of the private sector in the United States in helping to reinvent this country, over, and over, and over again, is important,” he said. “I think business has the talent, it has the resources, it has the capabilities of helping to change our country.” It's time to sweep the old concepts out of the saddle. The faster the drug market learns how to connect things differently, to 'see, say, sell and sustain' strategy at a system level, the faster it can start creating a different future for itself. #QuentinTarantino

10

1 Comment

NBRx story: Is #Patients or #NBRx or #NRx better metric for Incentive Compensation (IC) 1. Patient is an individual on therapy for a disease he/she is suffering. 2. NBRx is New Patient Start on a new drug. Sales reps feel they have more influence on NBRx in comparison to TRx, which they perceive as being more dependent on ongoing patient compliance. 3. NRx includes any new prescription: new-to-brand, new script, renewal of expired scripts. NRx remains a popular proxy for patient-oriented metrics. However, if it is used as Incentive Compensation (IC) metric, it may encourage the reps to influence HCPs to write shorter duration scripts, so they can get higher NRx volume. What the above means is that 1 patient can have multiple NBRx and each NBRx can have multiple NRx. NRx and TRx combinations are better metrics for IC. Example of Patient, NBRx and NRx: Patient A is suffering from NSCLC (type of lung cancer). > Physician puts this patient on Cisplatin (chemo therapy) for three months - First NBRx and also termed as NRx. >Now after three months of Cisplatin therapy, physician writes Cisplatin for two more months. This would be termed as another NRx >After Cisplatin, Physician switches the patient A to Opdivo (Immuno-oncology) for a month which would be termed as another NBRx as well as NRx Basically, there is 1 Patient A, 2 NBRx (Cisplatin & Opdivo) and 3 NRx (2 from Cisplatin and 1 Opdivo) (and 12 TRx, assuming Cisplatin as well as Opdivo are given every 15 days: 3 months + 2 months on Cisplatin and 1 month on Opdivo = 6 months * 2 TRx = 12 TRx) Source: My experience and IQVIA blog

10

Although only 1% of #pharmacy claims for commercial plans are for #specialtydrugs, these therapies often account for more than 50% of all prescription benefits spending. Let’s find a time to chat about how integrating clinical services and advanced data #analytics can help reduce specialty spend. https://okt.to/2glctO #wearemedimpact #atruepartner #healthcare #pharmacybenefits

5

Partnerships start with collaboration and an understanding of client culture. It is important to understand if a potential vendor shares the same values through a comprehensive RFP that also measures problem solving and personality traits. It is not about what you have....It is how you are going to customize an approach that best serves the client.

9

How to make your communications - ALL of them - crystal clear. Join John Jantsch and me for this Duct Tape Marketing podcast: https://lnkd.in/g2Yqi2B8

4

This article speaks to data visualization. Take a read. Once we secure information via insight or facts we have to find new ways to fully understand what’s being presented to us. If our internal teams do not understand an analysis, they can’t and will not use it. Find a way to help your people visualize the reality. https://lnkd.in/ergv6vRE

11

1 Comment

The Importance of Succession Planning: Securing Your Business's Future - A lack of robust business #successionplanning is the number one reason why family-run businesses struggle to endure the test of time. #Newmarket #Aurora #GTA #BusinessTips Learn more ⤵️⤵️⤵️ https://hubs.ly/Q02w3GmJ0

1

🌟 Overcoming Imposter Syndrome: Embrace Your Authenticity and Let go of Fear! 🌟 🌱 Did you know that approximately 70% of individuals experience imposter syndrome at some point in their lives? It's a common phenomenon that affects people across all demographics, with higher rates among women and individuals from the LGBTQ+ community. 💼 Imposter syndrome is prevalent in various professional sectors. For instance, those working in science and pharmaceuticals report the highest prevalence at 78%, followed by marketing and advertising at 72%. In high-pressure environments, like these, feelings of self-doubt and inadequacy are exacerbated, negatively impacting career progression and mental health. 🔍 Self-awareness is key! Acknowledge your feelings of imposter syndrome and understand that they're a normal part of the human experience. Reframe negative thoughts into positive affirmations and celebrate your achievements regularly 🎉. 👥 Seek support and mentorship from colleagues who can provide guidance and reassurance. Engage in continuous learning and skill development to boost your confidence and diminish feelings of inadequacy. 🌟 Let go of fear and embrace authenticity! By releasing fear and practicing self-compassion, individuals can transition from feeling like imposters to embracing their true, confident selves. 🌟 💚 Let's create supportive work environments where open discussions about imposter syndrome are encouraged, leading to personal growth and professional success! 💚 💡"Can you pinpoint where the fear stems from when you experience moments of self-doubt or imposter syndrome?" #Authenticity #OvercomingImposterSyndrome #CareerGrowth 🚀 #CoactiveCoach #Coaching #MentalFitness

15

5 Ways Pharma Brands Can Build Consumer Trust The pharmaceutical industry stands at a crossroads of trust and skepticism. Yet, this moment also presents an opportunity for pharma brands to strengthen consumer trust. Read this thought leadership piece by my colleague Courtney Kerwin highlighting five ways pharma brands can build consumer trust and drive deeper engagement with patients: I. ⛑️Ensuring Patient Safety: Rigorous drug testing and compliance are non-negotiable. The commitment to patient safety must be evident, especially when drugs reach the market swiftly. II. 🪟Transparency and Ethical Practices: Discussing pricing and marketing practices openly can enhance credibility and trust. III. 🧬Embracing Open Science and Collaboration: Sharing knowledge and democratizing data fosters a culture of trust and accelerates healthcare innovation. IV. 👏Empowering Patient Engagement: Involving patients in the healthcare journey ensures their voices are heard and their needs are met. V. 🎯Addressing Global Health Disparities: Equitable access to treatments and vaccines is crucial for building trust on a global scale. #Escalent has a deep legacy of helping pharma companies design and execute parent brand strategy efforts that are bigger than one medicine, and at the core of many of these studies is an emphasis on trust. #lifesciences #pharma #healthcare #buildingtrust To read in detail, follow the link ⬇: https://hubs.li/Q02vSWlZ0

9

The rise of Integrated Delivery Networks (IDNs) is changing the healthcare landscape. These networks employ nearly 70% of U.S. physicians. Pharma brand teams need diverse strategies to engage with stakeholders and navigate IDN systems. Learn more in this new article I authored along with my colleagues Gregory Skalicky, MBA and Faruk Abdullah. 

37

It’s time for pharma to rethink deployment models to meet evolving customer needs, as customer engagement preferences for both channel and frequency continue to change. My colleagues Scott Cohen and Megan Jackson take a closer look at declining access trends, address some of the top field deployment questions and offer tangible steps to evolve sales planning efforts. #oncology #pharma #futurecommercialmodel https://lnkd.in/eMEqApbn

12

Thoughts on this? >> Sanofi's trimmed oncology plans lead to $3B biobucks dent for IGM >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #healthcare #pharma

1